BUX Stock Overview
An oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Biomark Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.20 |
| 52 Week High | €0.32 |
| 52 Week Low | €0.18 |
| Beta | -0.46 |
| 11 Month Change | -14.58% |
| 3 Month Change | -14.58% |
| 1 Year Change | -26.79% |
| 33 Year Change | -21.15% |
| 5 Year Change | -26.79% |
| Change since IPO | 105.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| BUX | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -10.9% | -2.9% | 2.2% |
| 1Y | -26.8% | -5.4% | 23.4% |
Return vs Industry: BUX underperformed the Canadian Biotechs industry which returned -8.6% over the past year.
Return vs Market: BUX underperformed the Canadian Market which returned 23.4% over the past year.
Price Volatility
| BUX volatility | |
|---|---|
| BUX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine BUX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Rashid Ahmed Bux | www.biomarkdiagnostics.com |
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for women with dense breasts.
Biomark Diagnostics Inc. Fundamentals Summary
| BUX fundamental statistics | |
|---|---|
| Market cap | CA$13.03m |
| Earnings (TTM) | -CA$1.63m |
| Revenue (TTM) | CA$161.79k |
80.5x
P/S Ratio-8.0x
P/E RatioIs BUX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BUX income statement (TTM) | |
|---|---|
| Revenue | CA$161.79k |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$161.79k |
| Other Expenses | CA$1.79m |
| Earnings | -CA$1.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.018 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,008.61% |
| Debt/Equity Ratio | -119.6% |
How did BUX perform over the long term?
See historical performance and comparison